Connect
MJA
MJA

Chronic kidney disease and measurement of albuminuria or proteinuria: a position statement

David W Johnson, Graham R D Jones, Timothy H Mathew, Marie J Ludlow, Stephen J Chadban, Tim Usherwood, Kevan Polkinghorne, Stephen Colagiuri, George Jerums, Richard MacIsaac and Helen Martin, Australasian Proteinuria Consensus Working Group
Med J Aust 2012; 197 (4): 224-225. || doi: 10.5694/mja11.11468
  • David W Johnson1
  • Graham R D Jones2
  • Timothy H Mathew3
  • Marie J Ludlow3
  • Stephen J Chadban4
  • Tim Usherwood5
  • Kevan Polkinghorne6
  • Stephen Colagiuri7
  • George Jerums8
  • Richard MacIsaac8
  • Helen Martin9
  • Australasian Proteinuria Consensus Working Group

  • 1 Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD.
  • 2 Department of Chemical Pathology, St Vincent’s Hospital, Sydney, NSW.
  • 3 Kidney Health Australia, Adelaide, SA.
  • 4 Sydney Medical School, University of Sydney, Sydney, NSW.
  • 5 Department of General Practice, Sydney Medical School Westmead, Sydney, NSW.
  • 6 Department of Nephrology, Monash Medical Centre, Melbourne, VIC.
  • 7 Boden Institute of Obesity, Nutrition and Exercise, University of Sydney, Sydney, NSW.
  • 8 Department of Endocrinology and Diabetes, St Vincent's Hospital, Melbourne, VIC.
  • 9 Gribbles Pathology, Adelaide, SA.


Acknowledgements: 

David Johnson has received consulting fees or honoraria from Amgen, Roche, Shire, Genzyme, Boehringer-Ingelheim, Baxter Healthcare and Fresenius Medical Care; support for travel to meetings from Baxter, Amgen, Roche and Shire; and payment for development of educational presentations from the Australian College of Rural and Remote Medicine and the Northern Territory Division of General Practice. Graham Jones has received research support from Roche Diagnostics and support for travel to meetings from Roche Diagnostics and Bio-Rad. Stephen Chadban has received research support, travel assistance, consulting fees or honoraria from Amgen, Roche, Novartis, Genzyme, Wyeth and Bristol Myers Squibb. Richard MacIsaac has received speaker’s fees or travel support to attend meetings from Boehringer-Ingelheim, AstraZeneca, Eli Lilly, MSD, Novartis, Novo Nordisk and Sanofi Aventis. He has received grants from Novo Nordisk.

Competing interests:

David Johnson has received consulting fees or honoraria from Amgen, Roche, Shire, Genzyme, Boehringer-Ingelheim, Baxter Healthcare and Fresenius Medical Care; support for travel to meetings from Baxter, Amgen, Roche and Shire; and payment for development of educational presentations from the Australian College of Rural and Remote Medicine and the Northern Territory Division of General Practice.

  • 1. Johnson D; Caring for Australians with Renal Impairment. The CARI guidelines: evaluation of renal function. Nephrology (Carlton) 2005; 10 Suppl 4: S133-S176.
  • 2. Chadban SJ, Briganti EM, Kerr PG, et al. Prevalence of kidney damage in Australian adults: the AusDiab kidney study. J Am Soc Nephrol 2003; 14 (7 Suppl 2): S131-S138.
  • 3. White SL, Polkinghorne KR, Atkins RC, Chadban SJ. Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR estimating equations: the AusDiab (Australian Diabetes, Obesity and Lifestyle) Study. Am J Kidney Dis 2010; 55: 660-670.
  • 4. Johnson DW. Evidence-based guide to slowing the progression of early renal insufficiency. Intern Med J 2004; 34: 50-57.
  • 5. Mathew TH; Australasian Creatinine Consensus Working Group. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: a position statement. Med J Aust 2005; 183: 138-141. <MJA full text>
  • 6. Mathew TH, Johnson DW, Jones GR; Australasian Creatinine Consensus Working Group. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: revised recommendations. Med J Aust 2007; 187: 459-463. <MJA full text>
  • 7. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-2081.
  • 8. Ninomiya T, Perkovic V, de Galan BE, et al; ADVANCE Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009; 20: 1813-1821.
  • 9. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003; 63: 1468-1474.
  • 10. Hallan SI, Ritz E, Lydersen S, et al. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 2009; 20: 1069-1077.
  • 11. Hoy WE, Wang Z, VanBuynder P, et al. The natural history of renal disease in Australian Aborigines. Part 2. Albuminuria predicts natural death and renal failure. Kidney Int 2001; 60: 249-256.
  • 12. Hillege HL, Fidler V, Diercks GF, et al; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-1782.
  • 13. Iseki K, Kinjo K, Iseki C, Takishita S. Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan. Am J Kidney Dis 2004; 44: 806-814.
  • 14. Kissmeyer L, Kong C, Cohen J, et al. Community nephrology: audit of screening for renal insufficiency in a high risk population. Nephrol Dial Transplant 1999; 14: 2150-2155.
  • 15. Jones G. Urine albumin sampling and reporting — current practice in Australasia. The Clinical Biochemist Newsletter 2006; 163: 31-32. http://oldsite.aacb.asn.au/getfile/3123 (accessed Jul 2012).
  • 16. Jones GR. Laboratory reporting of urine protein and albumin. Clin Biochem Rev 2011; 32: 103-107.
  • 17. Atkins D, Best D, Briss PA, et al; GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490.
  • 18. Uhlig K, Macleod A, Craig J, et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 70: 2058-2065.
  • 19. American Diabetes Association. Standards of medical care in diabetes--2006. Diabetes Care 2006; 29 Suppl 1: S4-S42.
  • 20. Chadban S, Howell M, Twigg S, et al. National evidence based guideline for diagnosis, prevention and management of chronic kidney disease in type 2 diabetes. Canberra: Diabetes Australia and NHMRC, 2009. http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/di18-diabetes-kidney-disease.pdf (accessed Apr 2012).
  • 21. Crowe E, Halpin D, Stevens P; Guideline Development Group. Early identification and management of chronic kidney disease: summary of NICE guidance. BMJ 2008; 337: a1530.
  • 22. National Collaborating Centre for Chronic Conditions. Chronic kidney disease: national clinical guideline for early identification and management in adults in primary and secondary care. London: Royal College of Physicians, 2008. http://www.ncbi.nlm.nih.gov/books/NBK51773 (accessed Apr 2012).
  • 23. Methven S, MacGregor MS, Traynor JP, et al. Comparison of urinary albumin and urinary total protein as predictors of patient outcomes in CKD. Am J Kidney Dis 2010; 57: 21-28.
  • 24. de Zeeuw D. Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? Kidney Int Suppl 2004; (92): S2-S6.
  • 25. Hallan S, Astor B, Romundstad S, et al. Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals: the Hunt II Study. Arch Intern Med 2007; 167: 2490-2496.
  • 26. Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110: 2809-2816.
  • 27. Färbom P, Wahlstrand B, Almgren P, et al. Interaction between renal function and microalbuminuria for cardiovascular risk in hypertension: the Nordic Diltiazem Study. Hypertension 2008; 52: 115-122.
  • 28. Lamb EJ, MacKenzie F, Stevens PE. How should proteinuria be detected and measured? Ann Clin Biochem 2009; 46: 205-217.
  • 29. Miller WG, Bruns DE, Hortin GL, et al; National Kidney Disease Education Program-IFCC Working Group on Standardization of Albumin in Urine. Current issues in measurement and reporting of urinary albumin excretion. Clin Chem 2009; 55: 24-38.
  • 30. Scottish Intercollegiate Guidelines Network. Diagnosis and management of chronic kidney disease: a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network, 2008. http://www.sign.ac.uk/pdf/sign103.pdf (accessed Apr 2012).
  • 31. Eckardt KU, Berns JS, Rocco MV, Kasiske BL. Definition and classification of CKD: the debate should be about patient prognosis — a position statement from KDOQI and KDIGO. Am J Kidney Dis 2009; 53: 915-920.
  • 32. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089-2100.
  • 33. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (2 Suppl 1): S1-S266.
  • 34. Saudan PJ, Brown MA, Farrell T, Shaw L. Improved methods of assessing proteinuria in hypertensive pregnancy. Br J Obstet Gynaecol 1997; 104: 1159-1164.
  • 35. Kidney Health Australia. Chronic kidney disease (CKD) management in general practice. Melbourne: Kidney Health Australia, 2007.
  • 36. National Aboriginal Community Controlled Health Organisation. National guide to a preventive health assessment in Aboriginal and Torres Strait Islander peoples. South Melbourne: Royal Australian College of General Practitioners, 2005. http://www.naccho.org.au/Files/Documents/National%20guide%20to%20preventive%20health%20assessment.pdf (accessed Apr 2012).
  • 37. National Heart Foundation. Hypertension management guide for doctors, 2004. Deakin, ACT: National Heart Foundation of Australia, 2003.
  • 38. Royal Australian College of General Practitioners. Guidelines for preventive activities in general practice. 7th ed. South Melbourne: RACGP, 2009. http://www.racgp.org.au/Content/NavigationMenu/ClinicalResources/RACGPGuidelines/TheRedBook/redbook_7th_edition_May_2009.pdf (accessed Apr 2012).
  • 39. Caring for Australians with Renal Impairment. The CARI guidelines. Urine protein as diagnostic test: performance characteristics of tests used in the initial evaluation of patients at risk of renal disease. Nephrology (Carlton) 2004; 9 Suppl 3: S8-S14.
  • 40. Craig JC, Barratt A, Cumming R, et al. Feasibility study of the early detection and treatment of renal disease by mass screening. Intern Med J 2002; 32: 6-14.
  • 41. White S, Yu R, Craig JC, et al. Diagnostic accuracy of urine dipsticks for detection of albuminuria in the general community. Am J Kidney Dis 2011; 58: 19-28.
  • 42. Witte EC, Lambers Heerspink HJ, de Zeeuw D, et al. First morning voids are more reliable than spot urine samples to assess microalbuminuria. J Am Soc Nephrol 2009; 20: 436-443.
  • 43. Price CP, Newall RG, Boyd JC. Use of protein:creatinine ratio measurements on random urine samples for prediction of significant proteinuria: a systematic review. Clin Chem 2005; 51: 1577-1586.
  • 44. Côté AM, Brown MA, Lam E, et al. Diagnostic accuracy of urinary spot protein:creatinine ratio for proteinuria in hypertensive pregnant women: systematic review. BMJ 2008; 336: 1003-1006.
  • 45. Bakker AJ. Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration. Diabetes Care 1999; 22: 307-313.
  • 46. Johnson DW, Mathew T. Managing chronic kidney disease. Medicine Today 2007; 8: 37-45. http://www.medicinetoday.com.au/home/article/view/648 (accessed Jul 2012)
  • 47. Kidney Health Australia. Chronic kidney disease (CKD) management in general practice. 2nd ed. Melbourne: KHA, 2012.
  • 48. Royal Australian College of General Practitioners. Guidelines for preventive activities in general practice. 8th ed. South Melbourne: RACGP, 2012. In press.
  • 49. Younes N, Cleary PA, Steffes MW, et al; DCCT/EDIC Research Group. Comparison of urinary albumin-creatinine ratio and albumin excretion rate in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Clin J Am Soc Nephrol 2010; 5: 1235-1242. doi: 10.2215/CJN.07901109.
  • 50. Houlihan CA, Tsalamandris C, Akdeniz A, Jerums G. Albumin to creatinine ratio: a screening test with limitations. Am J Kidney Dis 2002; 39: 1183-1189.
  • 51. Kramer HM, Hsu CY, Curhan G. Need for sex-specific ACR. Am J Kidney Dis 2002; 40: 435-436.
  • 52. Warram JH, Gearin G, Laffel L, Krolewski AS. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol 1996; 7: 930-937.
  • 53. Mattix HJ, Hsu CY, Shaykevich S, Curhan G. Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race. J Am Soc Nephrol 2002; 13: 1034-1039.
  • 54. de Boer IH, Astor BC, Kramer H, et al. Mild elevations of urine albumin excretion are associated with atherogenic lipoprotein abnormalities in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2008; 197: 407-414.
  • 55. de Boer IH, Ioannou GN, Kestenbaum B, et al. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2007; 50: 69-77.
  • 56. Incerti J, Zelmanovitz T, Camargo JL, et al. Evaluation of tests for microalbuminuria screening in patients with diabetes. Nephrol Dial Transplant 2005; 20: 2402-2407.
  • 57. Mogensen CE, Keane WF, Bennett PH, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346: 1080-1084.
  • 58. Methven S, MacGregor MS, Traynor JP, et al. Assessing proteinuria in chronic kidney disease: protein-creatinine ratio versus albumin-creatinine ratio. Nephrol Dial Transplant 2010; 25: 2991-2996.
  • 59. Ellam TJ, El Nahas M. Proteinuria thresholds are irrational: a call for proteinuria indexing. Nephron Clin Pract 2011; 118: c217-c224.
  • 60. Atkins RC, Briganti EM, Zimmet PZ, Chadban SJ. Association between albuminuria and proteinuria in the general population: the AusDiab Study. Nephrol Dial Transplant 2003; 18: 2170-2174.
  • 61. McIntyre NJ, Taal MW. How to measure proteinuria? Curr Opin Nephrol Hypertens 2008; 17: 600-603.
  • 62. Ohisa N, Yoshida K, Matsuki R, et al. A comparison of urinary albumin-total protein ratio to phase-contrast microscopic examination of urine sediment for differentiating glomerular and nonglomerular bleeding. Am J Kidney Dis 2008; 52: 235-241.
  • 63. Australasian Creatinine Consensus Working Group. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: new developments and revised recommendations. Med J Aust 2012; 197: 224-225.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.